|
|
|
|
|
|
|
|
open access
Conclusion
This review will discuss the
different PARP inhibitors in development and the potential use of this
class of agents in the future. Moreover, combination strategies
involving PARP inhibitors are likely to receive increasing attention.
The utility of PARP inhibitors combined with cytotoxic chemotherapy is
of doubtful value, because of enhanced toxicity of this combination;
while, more promising strategies include the combination with
antiangiogenic agents, or with inhibitors of the P13K/AKT pathway and
new generation of immunotherapy.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.